Glioma
Glioma is a broad category of primary central nervous system tumors arising from glial lineage cells in the brain and spinal cord.
Glioma is a broad category of primary central nervous system tumors arising from glial lineage cells in the brain and spinal cord. It includes biologically and clinically diverse entities, ranging from lower-grade diffuse gliomas to highly aggressive forms such as glioblastoma. In recent research, glioma is consistently described as a highly malignant, invasive, and recurrent brain cancer with poor prognosis, substantial therapeutic resistance, and a strongly immunosuppressive tumor microenvironment.
Molecularly, glioma research increasingly focuses on alterations such as IDH mutation status, BRAF alterations, met/c-met signaling, Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) pathway activity, ferroptosis-related mechanisms, immune evasion, and metabolic reprogramming, including methionine and glucose metabolism. The disease is also a major target for advanced imaging, radiogenomics, liquid biopsy, and precision oncology approaches aimed at improving diagnosis, molecular classification, prognosis, and treatment selection.
Where the papers sit
15 papers from the last 6 months study glioma directly · updated from PubMed 11 Oct 2026
Study type 0 clinical trials · 3 observational · 3 human data · 6 preclinical · 3 unclassified
Themes one subject · 1 paradigm shift
Those 15 are all about one subject.
-
Glioma Biology and Clinical Care
H3K27M stemness, IDH-mutant spatial evolution, and tumour cellular programs anchor work on glioma biology. Therapeutic studies range from temozolomide toxicity management and cyclophosphamide chemo-immunotherapy to intrathecal treatment, targeted nucleic-acid delivery, irradiation, and CAR-T cells for antigen-heterogeneous disease. Diagnosis and monitoring efforts use MRI segmentation and classification, electrical bioimpedance, plasma extracellular vesicles, and SIL1 prognostic assessment. Surgical workflows and immune mechanisms, including distal B-cell responses in tumour-draining lymph nodes, broaden the clinical focus without establishing a single field-wide direction.
Effective glioma immunotherapy depends on mobilizing immune responses beyond the tumor itself
The CTLA-4 blockade study in glioma-bearing mice 42430444Jul and the armored CAR-T study in antigen-heterogeneous orthotopic glioma 42159488May instead identify host immune cooperation as a therapeutic requirement or mechanism: CTLA-4 efficacy required germinal-center B-cell responses in tumor-draining cervical lymph nodes and antibody accumulation in the tumor, while cytokine-armored CAR-T cells were designed to reverse local immunosuppression and engage endogenous immunity. This challenges the framing of glioma treatment as primarily a problem of delivering cytotoxic agents or engineered cells across tumor barriers and shows that effective therapy can depend on activating immune circuits outside the tumor and coordinating them with local antitumor activity.
Papers
The 15 papers from the last 6 months that study glioma directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Glioma Biology and Clinical Care (15)
- Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors. International journal of pharmaceutics · 27 Sept 2026 PMID 42801996
- H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids. Cell stem cell · 16 Sept 2026 PMID 42748922
- Spatial analysis reveals the evolving organization of IDH-mutant glioma. Cancer cell · 14 Sept 2026 PMID 42735681
- Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica terapeutica · 28 Aug 2026 PMID 42664125
- W-AGRU-Net: a dual-stream attention framework for robust brain tumor segmentation in clinical MRI imaging. Scientific reports · 27 Aug 2026 PMID 42660973
- A novel hybrid transformer-based framework (H-ConvNeXt-Swin) to classify brain tumors using MRI. Scientific reports · 5 Aug 2026 PMID 42557264
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- GliomaDeconv maps glioma-specific cellular programs from bulk transcriptomic profiles and reveals spatiotemporal associations with progression and treatment response. Cancer letters · 7 Jul 2026 PMID 42413813
- Assessing the prognostic value of SIL1 in pan-cancer cohorts and its practical application as a biomarker in glioma practice. BMC cancer · 29 Jun 2026 PMID 42374254
- Repurposing of cyclophosphamide as a chemo‑immunotherapy agent in glioma using D8/RI‑VAP modified-chitosan nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jun 2026 PMID 42341589
- PATHY-inspired partial tumor irradiation on a small-animal irradiator: workflow development and first therapeutic evaluation in glioma. Physics in medicine and biology · 22 May 2026 PMID 42173137
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. Cancer research · 20 May 2026 PMID 42159488
- Minimally-invasive resection of deep-seated subcortical and intraventricular lesions using an integrated camera-port system: A retrospective case series. PloS one · 11 May 2026 PMID 42113762
- Combined multi-omics and multi-spectral profiling of plasma extracellular vesicles reveals liquid biopsy biomarkers for glioma diagnosis. Cell reports. Medicine · 18 Apr 2026 PMID 41999751
- Brain tumors classification using electrical bioimpedance spectroscopy based on a multi-scale feature extraction network with frequency band attention mechanism. Biomedical physics & engineering express · 15 Apr 2026 PMID 41985487
By study type
Observational studies and case reports (3)
- Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica terapeutica · 28 Aug 2026 PMID 42664125
- Minimally-invasive resection of deep-seated subcortical and intraventricular lesions using an integrated camera-port system: A retrospective case series. PloS one · 11 May 2026 PMID 42113762
- Combined multi-omics and multi-spectral profiling of plasma extracellular vesicles reveals liquid biopsy biomarkers for glioma diagnosis. Cell reports. Medicine · 18 Apr 2026 PMID 41999751
Human data, design not indexed (3)
- W-AGRU-Net: a dual-stream attention framework for robust brain tumor segmentation in clinical MRI imaging. Scientific reports · 27 Aug 2026 PMID 42660973
- A novel hybrid transformer-based framework (H-ConvNeXt-Swin) to classify brain tumors using MRI. Scientific reports · 5 Aug 2026 PMID 42557264
- Brain tumors classification using electrical bioimpedance spectroscopy based on a multi-scale feature extraction network with frequency band attention mechanism. Biomedical physics & engineering express · 15 Apr 2026 PMID 41985487
Preclinical: animal, cell and lab studies (6)
- Spatial analysis reveals the evolving organization of IDH-mutant glioma. Cancer cell · 14 Sept 2026 PMID 42735681
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- GliomaDeconv maps glioma-specific cellular programs from bulk transcriptomic profiles and reveals spatiotemporal associations with progression and treatment response. Cancer letters · 7 Jul 2026 PMID 42413813
- Repurposing of cyclophosphamide as a chemo‑immunotherapy agent in glioma using D8/RI‑VAP modified-chitosan nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jun 2026 PMID 42341589
- PATHY-inspired partial tumor irradiation on a small-animal irradiator: workflow development and first therapeutic evaluation in glioma. Physics in medicine and biology · 22 May 2026 PMID 42173137
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. Cancer research · 20 May 2026 PMID 42159488
Unclassified: not yet indexed with MeSH (3)
- Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors. International journal of pharmaceutics · 27 Sept 2026 PMID 42801996
- H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids. Cell stem cell · 16 Sept 2026 PMID 42748922
- Assessing the prognostic value of SIL1 in pan-cancer cohorts and its practical application as a biomarker in glioma practice. BMC cancer · 29 Jun 2026 PMID 42374254
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-07-12. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.